TY - JOUR
T1 - Nicotinamide inhibits nuclear factor-kappa B translocation after transient focal cerebral ischemia
AU - Chen, Tsung Ying
AU - Lin, Miao Hui Sylvia
AU - Lee, Wei Ting
AU - Huang, Sheng Yang
AU - Chen, Ying Hsin
AU - Lee, Ai Chiang
AU - Lin, Hsiao Wen
AU - Lee, E. Jian
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Objective: We explored the putative anti-inflammatory effects of nicotinamide against experimental stroke. Design: Prospective laboratory study. Setting: Research laboratory in a university teaching hospital. Subjects: Adult male Sprague-Dawley rats (250-300 g). Interventions: The antioxidant, radical scavenging, and anti-inflammatory actions of nicotinamide were evaluated using a panel of acellular assays and lipopolysaccharide-stimulated RAW 264.7 and BV2 cells. Animals were subjected to transient middle cerebral artery occlusion for 90 mins. Nicotinamide (500 mg/kg) or vehicle was given intravenously at reperfusion onset. Measurements and Main Results; Nicotinamide effectively inhibited nuclear factor-κB translocation and binding activity as well as the production of tumor necrosis factor-α, nitrite/nitrate, and interleukin-6 in the lipopolysaccharide-stimulated RAW 264.7 and BV2 cells (p < .05, respectively) but exhibited weak antioxidant and radical-scavenging actions. Relative to controls, nicotinamide-treated animals had significant reductions in neutrophil and macrophage/activated microglial infiltration in the ischemic brain by 53% and 77% (p < .05, respectively). Additionally, nicotinamide significantly attenuated phosphorylation of nuclear factor-κB's inhibitory protein, nuclear factor-κB translocation and binding activity, and the synthesis of inducible nitric oxide in the ischemic brain (p < .05, respectively). Consequently, nicotinamide effectively reduced brain infarction and improved neurobehavioral outcome by 43% and 50% (p < .05, respectively). Conclusions: Nicotinamide effectively attenuated postischemic nuclear factor-kappa]B activation and exhibited robust anti-inflammatory actions against ischemic stroke.
AB - Objective: We explored the putative anti-inflammatory effects of nicotinamide against experimental stroke. Design: Prospective laboratory study. Setting: Research laboratory in a university teaching hospital. Subjects: Adult male Sprague-Dawley rats (250-300 g). Interventions: The antioxidant, radical scavenging, and anti-inflammatory actions of nicotinamide were evaluated using a panel of acellular assays and lipopolysaccharide-stimulated RAW 264.7 and BV2 cells. Animals were subjected to transient middle cerebral artery occlusion for 90 mins. Nicotinamide (500 mg/kg) or vehicle was given intravenously at reperfusion onset. Measurements and Main Results; Nicotinamide effectively inhibited nuclear factor-κB translocation and binding activity as well as the production of tumor necrosis factor-α, nitrite/nitrate, and interleukin-6 in the lipopolysaccharide-stimulated RAW 264.7 and BV2 cells (p < .05, respectively) but exhibited weak antioxidant and radical-scavenging actions. Relative to controls, nicotinamide-treated animals had significant reductions in neutrophil and macrophage/activated microglial infiltration in the ischemic brain by 53% and 77% (p < .05, respectively). Additionally, nicotinamide significantly attenuated phosphorylation of nuclear factor-κB's inhibitory protein, nuclear factor-κB translocation and binding activity, and the synthesis of inducible nitric oxide in the ischemic brain (p < .05, respectively). Consequently, nicotinamide effectively reduced brain infarction and improved neurobehavioral outcome by 43% and 50% (p < .05, respectively). Conclusions: Nicotinamide effectively attenuated postischemic nuclear factor-kappa]B activation and exhibited robust anti-inflammatory actions against ischemic stroke.
UR - http://www.scopus.com/inward/record.url?scp=84856222460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856222460&partnerID=8YFLogxK
U2 - 10.1097/CCM.0b013e31822f0b08
DO - 10.1097/CCM.0b013e31822f0b08
M3 - Article
C2 - 21926578
AN - SCOPUS:84856222460
SN - 0090-3493
VL - 40
SP - 532
EP - 537
JO - Critical care medicine
JF - Critical care medicine
IS - 2
ER -